Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure with preserved ejection fraction, but additional data …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …

Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …

Hospitalization for major diabetes complications, including myocardial infarction, stroke,
lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a …

BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with
type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF …

In modern cardiology, sodium‐glucose cotransporter 2 (SGLT2) inhibitors are critical
components of heart failure (HF) treatment algorithms and exert their effects primarily by …

Background: Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote
reverse cardiac remodeling in people with diabetes or heart failure. Although it has been …